What was the market valuation of the UK human growth-hormone market in 2024?

The market valuation was $310.0 Million in 2024. Read More

What is the projected market valuation for the UK human growth-hormone market by 2035?

The projected valuation for 2035 is $1010.0 Million. Read More

What is the expected CAGR for the UK human growth-hormone market during the forecast period 2025 - 2035?

The expected CAGR is 11.34% during the forecast period 2025 - 2035. Read More

Which companies are considered key players in the UK human growth-hormone market?

Key players include Pfizer, Eli Lilly and Company, Merck KGaA, Novartis, Boehringer Ingelheim, Sandoz, Hikma Pharmaceuticals, Ferring Pharmaceuticals, and Ipsen. Read More

What are the leading brands in the UK human growth-hormone market and their valuations?

Leading brands include Norditropin ($80.0 - $250.0 Million), Genotropin ($70.0 - $220.0 Million), and Humatrope ($50.0 - $160.0 Million). Read More

What routes of administration are prevalent in the UK human growth-hormone market?

Prevalent routes include Subcutaneous ($100.0 - $320.0 Million), Intramuscular ($90.0 - $290.0 Million), and Intravenous ($120.0 - $400.0 Million). Read More

What applications are driving the UK human growth-hormone market?

Driving applications include Adult Growth Hormone Deficiency ($80.0 - $250.0 Million) and Pediatric Growth Hormone Deficiency ($50.0 - $160.0 Million). Read More

How is the distribution of human growth-hormones structured in the UK market?

Distribution channels include Hospital Pharmacies ($80.0 - $260.0 Million) and Specialty Pharmacy ($110.0 - $370.0 Million). Read More

What is the market performance of the 'Others' segment in the brand category?

The 'Others' segment in the brand category ranges from $20.0 to $90.0 Million. Read More

How does the market for human growth-hormones appear to be evolving in the UK?

The market appears to be evolving positively, with a projected growth trajectory leading to $1010.0 Million by 2035. Read More

UK Human Growth Hormone Market

ID: MRFR/HC/43242-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

UK Human Growth Hormone Market Research Report: Size, Share, Trend Analysis By Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, Others), By Route of Administration (Subcutaneous, Intramuscular, Intravenous), By Applications (Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency, Idiopathic Growth Hormone Deficiency, Small for Gestational Age, Turner Syndrome, Prader-Willi Syndrome, Others) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacy, Specialty Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035

UK Human Growth Hormone Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)11.34%

2024 Market Size$ 310 Million

2025 Market Size$ 345.15 Million

2035 Market Size$ 1,010 Million

Key Players

Pfizer

Eli Lilly and Company

Merck KGaA

Novartis

Boehringer Ingelheim

Sandoz

Trends

Rising Demand for Anti-Aging Treatments
Technological Advancements in Production
Regulatory Changes and Compliance

Opportunities

Evolving Regulatory Landscape
Advancements in Medical Research
Rising Fitness and Wellness Trends

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Brand (USD Million)
  1. 4.1.1 Norditropin
  2. 4.1.2 Genotropin
  3. 4.1.3 Humatrope
  4. 4.1.4 Saizen
  5. 4.1.5 Omnitrope
  6. 4.1.6 Skytrofa
  7. 4.1.7 Others
2. 4.2 Food, Beverages & Nutrition, BY Route of Administration (USD Million)
  1. 4.2.1 Subcutaneous
  2. 4.2.2 Intramuscular
  3. 4.2.3 Intravenous
3. 4.3 Food, Beverages & Nutrition, BY Application (USD Million)
  1. 4.3.1 Pediatric Growth Hormone Deficiency
  2. 4.3.2 Adult Growth Hormone Deficiency
  3. 4.3.3 Idiopathic Growth Hormone Deficiency
  4. 4.3.4 Small for Gestational Age
  5. 4.3.5 Turner Syndrome
  6. 4.3.6 Prader-Willi Syndrome
  7. 4.3.7 Others
4. 4.4 Food, Beverages & Nutrition, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Online Pharmacy
  4. 4.4.4 Specialty Pharmacy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Eli Lilly and Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck KGaA (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Boehringer Ingelheim (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sandoz (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Hikma Pharmaceuticals (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Ferring Pharmaceuticals (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Ipsen (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY BRAND
3. 6.3 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 UK MARKET ANALYSIS BY APPLICATION
5. 6.5 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY BRAND, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY BRAND, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY APPLICATION, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY BRAND, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Brand (USD Million, 2025-2035)

Norditropin
Genotropin
Humatrope
Saizen
Omnitrope
Skytrofa
Others

Food, Beverages & Nutrition By Route of Administration (USD Million, 2025-2035)

Subcutaneous
Intramuscular
Intravenous

Food, Beverages & Nutrition By Application (USD Million, 2025-2035)

Pediatric Growth Hormone Deficiency
Adult Growth Hormone Deficiency
Idiopathic Growth Hormone Deficiency
Small for Gestational Age
Turner Syndrome
Prader-Willi Syndrome
Others

Food, Beverages & Nutrition By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacy
Specialty Pharmacy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”